2024
Short-Term Out-of-Pocket and Total Costs of Care After Ablation, Resection, or Transplant for Early-Stage Hepatocellular Carcinoma: A National SEER-Medicare Cost Comparison.
Charalel R, Mushlin A, Zheng X, Mao J, Carlos R, Brown R, Ibrahim S, Fortune B, Talenfeld A, Madoff D, Johnson M, Sedrakyan A. Short-Term Out-of-Pocket and Total Costs of Care After Ablation, Resection, or Transplant for Early-Stage Hepatocellular Carcinoma: A National SEER-Medicare Cost Comparison. American Journal Of Roentgenology 2024, 223: e2431272. PMID: 38899842, DOI: 10.2214/ajr.24.31272.Peer-Reviewed Original ResearchEarly-stage hepatocellular carcinomaHepatocellular carcinomaPost-procedure periodIndex procedureOut-of-pocket costsPatient out-of-pocket costsDrivers of high costsDays post-procedureSubgroup of patientsTreated with ablationPropensity-matched subgroupsU.S. population-based studyPopulation-based studySurgical resectionMultivariate linear regression modelSurgical treatmentPrognostic indicatorPost-procedureTreatment modalitiesTreatment optionsSEER-MedicareResectionMultivariate analysisTransplantationPropensity-score
2005
Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors
Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, Hicks ME, Rao S, Vauthey J, Ajani JA, Yao JC. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors. Cancer 2005, 104: 1590-1602. PMID: 16134179, DOI: 10.1002/cncr.21389.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoid TumorCarcinoma, Islet CellChemoembolization, TherapeuticDisease-Free SurvivalEmbolization, TherapeuticFemaleFollow-Up StudiesHepatic ArteryHumansLiver NeoplasmsMaleMedical RecordsMiddle AgedPrognosisRetrospective StudiesRisk FactorsSurvival RateConceptsHepatic arterial embolizationProgression-free survivalIslet cell carcinomaMetastatic neuroendocrine tumorsIntact primary tumorOverall survivalCarcinoid tumorsCell carcinomaHigh response rateNeuroendocrine tumorsMultivariate analysisArterial embolizationBone metastasesPrimary tumorMale genderRisk factorsPrognostic variablesResponse rateOnly independent risk factorLonger progression-free survivalPancreatic islet cell carcinomaExtensive liver diseaseOutcomes of patientsIndependent risk factorOnly risk factor